Patents Examined by Brian-Yong Kwon
  • Patent number: 6303581
    Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: October 16, 2001
    Inventor: Dale L. Pearlman
  • Patent number: 6300365
    Abstract: The present invention is directed to methods for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: October 9, 2001
    Inventor: Andrew J. Holman
  • Patent number: 6294581
    Abstract: The production of IgA is selectively inhibited by orally administering 15-deoxyspergualin or pharmacologically acceptable salts thereof, thus preventing and treating IgA-associated immunological diseases such as IgA nephropathy.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: September 25, 2001
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Kazutoh Takesako, Hideharu Saito, Ikunoshin Kato
  • Patent number: 6281241
    Abstract: The invention relates to the use of melatonin and melatonin-containing preparations for the treatment of androgenetic alopecia of the female type.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: August 28, 2001
    Assignee: ASAT AG Applied Science and Technology
    Inventor: Peter Elsner
  • Patent number: 6277875
    Abstract: The present invention is directed to metho s for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: August 21, 2001
    Inventor: Andrew J. Holman
  • Patent number: 6268377
    Abstract: The present invention provides for the combined use of 5&agr;-reductase inhibitors together with calcium channel blockers for the treatment of benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, hematuria, and other androgen related disorders, including prostatitis and the prevention of prostate cancer. This invention provides a method of treatment which is useful in the treatment of benign prostatic hyperplasia, prostatitis, and/or the prevention and treatment of prostatic cancer, as well as in the treatment of prostatitis and hematuria. This invention also provides a pharmaceutical composition which is useful in the treatment of benign prostatic hyperplasia, prostatitis, hematuria and/or the prevention and treatment of prostatic cancer, wherein the pharmaceutical composition comprises the combination of a 5&agr;-reductase inhibitor and a calcium channel blocking agent.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: July 31, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Joanne Waldstreicher, Daniel Z. Wang
  • Patent number: 6268359
    Abstract: A pharmaceutical composition for preventing or treating visual function disorders caused by ocular circulatory disorders (for example, ocular hypertension and glaucoma) and visual function disorders based on ciliary tension (for example, myopia) whose active component is a vasopressin antagonist.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: July 31, 2001
    Assignees: Senju Pharmaceutical Co., Ltd., Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Takahiro Ogawa, Noriko Watanabe, Mitsunori Waki
  • Patent number: 6265384
    Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: July 24, 2001
    Inventor: Dale L. Pearlman